Ken Fisher
PTGX icon

Ken Fisher’s Protagonist Therapeutics PTGX Stock Holding History

Ken Fisher’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.3M Buy
173,971
+108,857
+167% +$9.64M 0.01% 339
2025
Q4 		$5.69M Buy
+65,114
New +$5.33M ﹤0.01% 451

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Ken Fisher's PTGX Position: Q1 2026 in Review

Ken Fisher increased its Protagonist Therapeutics (PTGX) stake by 167% in Q1 2026, buying an estimated $9.64M and bringing the position to 173,971 shares worth $18.3M. The position accounts for 0.01% of the portfolio, ranked #339.

Ken Fisher first reported a position in PTGX in Q4 2025 and has held it in 2 quarters since. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Ken Fisher held 173,971 shares of Protagonist Therapeutics worth $18.3M as of Q1 2026.
  • Ken Fisher bought 108,857 Protagonist Therapeutics shares in Q1 2026, an estimated $9.64M.
  • Protagonist Therapeutics made up 0.01% of Ken Fisher's portfolio in Q1 2026, its #339 holding.
  • Ken Fisher first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.